Many diseases have not yet been conquered, and numerous patients are still struggling with such diseases. Although new therapeutics, including antibody drugs, have been developed, there are still many unmet medical needs. Our mission is to make contributions to global medical care with our unique antibody technologies, which we have developed through years of research.
Perseus Proteomics was established in 2001 based on advanced technologies and the diversified research network of the Research Center for Advanced Science and Technology of the University of Tokyo, and we have been focusing on the discovery of new antibodies with great effort since then. Since our foundation, we have contributed to drug discovery research through the research and development of reagents and diagnostics, providing a full panel of antibodies against 48 nuclear receptors and a biomarker detecting system for vascular inflammation. Taking advantage of our abundant experience and know-how in research on antibodies, we are diligently working on the discovery of new antibody drugs, including engineered antibodies, modified antibodies (RIT, ADC), and fully human antibodies.
Among antibodies that we have discovered for cancer treatment, an antibody targeting solid tumors has been licensed to a pharmaceutical company and is currently being evaluated in a clinical trial. Since 2014, another antibody targeting hematological malignancies has been developed under the support of the “Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP)", which is funded by Japan Agency for Medical Research and Development (AMED). In 2018, it was switched to industry-sponsored development and the development is currently ongoing. We are also conducting research and development for several other antibodies for cancer treatment, such as antibody-drug conjugates (ADCs) for refractory solid tumors, and therapeutic antibodies for other diseases.
An advantage of our drug discovery is that we can efficiently obtain new antibodies with high pharmacological activity as therapeutics. However, the concern is how promptly we can deliver these antibodies as drugs to patients. We, as a partner of pharmaceutical companies, focus on delivering antibody drugs to patients as fast as possible. Technologies and research/development environments concerning pharmaceutical products are constantly changing. We further strengthen the collaboration with research institutions such as pharmaceutical companies and universities and always integrate cutting-edge technologies with our technologies to discover better antibody drug seeds. This is our contribution to future medical care.
Remark: Please note that this is translated as per the original text; however, its intended meaning is unclear. Please check and clarify.
President & CEO